Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory capital notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of February 27, 2015:
- Total Issued Ordinary Shares: 5,356,352,396 (25p each)
- Treasury Shares: 491,515,950
- Total Voting Rights: 4,864,836,446
No comparative data for prior periods is included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to capital structure disclosure.
Investor Verification Checklist
- Verify the total number of voting rights (4,864,836,446) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,515,950) as of February 27, 2015.
- Review the Company's Form 20-F for comprehensive financial performance data not included in this 6-K.